


Co jste kdy (ne)chtěli vědět o strukturách SARS-CoV-2

Karel Berka


KFC PŘF UPOL



Osnova

SARS-CoV-2

- Genom
- Proteiny
 - Viru
 - Hostitele
- Virová kapsle
- Life cycle viru
- Léčba
- Vakcíny




Life Cycle

Life expectancy bounce-backs amid continued losses

Life expectancy changes since the start of the COVID-19 pandemic



Estimates for 2021 are adjusted for the weeks with missing data in 2021



Life Cycle of SARS-CoV-2

<https://www.youtube.com/watch?v=k2GlafQ9YhY>


Life Cycle of SARS-CoV-2



<https://www.nature.com/articles/s41579-020-00468-6/figures/1>

<http://pdb101.rcsb.org/sci-art/goodsell-gallery/coronavirus-life-cycle>

Virus Genome/Proteome




Genom SARS-Cov-2


RNA+ virus

29,903 b

12 coding genes – ORF1ab v sobě obsahuje 16 nsp proteinů



Struktury proteinů





X Cell survival
 Virus assembly
 RNA synthesis
 RNA editing
 Proteases
 Host attachment




- <https://cdn.rcsb.org/pdb101/learn/resources/flyers/covid-genome/covid-genome-prots.png>

SARS-CoV-2 proteiny

- Replicase polyprotein 1ab
 - **Multifunctional protein involved in the transcription and replication** of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein.
- Host translation inhibitor nsp1
 - Inhibits **host translation** by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response.
- Non-structural protein 2 (nsp2)
 - **modulation of host cell survival signaling pathway by interacting with host PHB and PHB2.** Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses
- Non-structural protein 3 (nsp3) - PL-PRO
 - Responsible for the **cleavages of polyprotein**



- **Non-structural protein 4 (nsp4)**
 - **assembly of virally-induced cytoplasmic double-membrane vesicles** necessary for viral replication.
- **3C-like proteinase (3CL-PRO)**
 - **Cleaves** the C-terminus of **replicase polyprotein** at 11 sites
- **Non-structural protein 6 (nsp6)**
 - initial **induction of autophagosomes** from host reticulum endoplasmic. Later, limits the expansion of these phagosomes that are no longer able to deliver viral components to lysosomes
- **Non-structural protein 7 (nsp7)**
 - **viral RNA synthesis**
- **Non-structural protein 8 (nsp8)**
 - **viral RNA synthesis**
- **Non-structural protein 9 (nsp9)**
 - viral replication by acting as a **ssRNA-binding protein**.
- **Non-structural protein 10 (nsp10)**
 - viral mRNAs **cap methylation**



- RNA-directed RNA polymerase (Pol)

- Responsible for **replication and transcription** of the viral RNA genome.

- Helicase (Hel)

- RNA and DNA **duplex-unwinding** activities with 5' to 3' polarity

- Proofreading exoribonuclease (ExoN)






- **exoribonuclease** activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity.

- Uridylate-specific endoribonuclease



- Mn(2+)-dependent, uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to the **cleaved** bond.

- 2'-O-methyltransferase

- mRNA **cap 2'-O-ribose** methylation to the **5'-cap structure** of viral mRNAs. - to evade immune system



- **Spike glycoprotein (S protein)**
 - **attaches** the virion to the cell membrane by binding to human **ACE2 receptor**
- **ORF3a protein (ORF3a)**
 - potassium sensitive ion channels (**viroporin**) and may modulate virus release. Up-regulates expression of fibrinogen subunits FGA, FGB and FGG in host lung epithelial cells. Induces apoptosis in cell culture
- **Envelope small membrane protein (E)**
 - central role in **virus morphogenesis and assembly**. Acts as a viroporin and self-assembles in host membranes forming pentameric protein-lipid pores that allow ion transport. Also plays a role in the induction of apoptosis
- **Membrane protein (M)**
 - viral envelope that plays a central role in **virus morphogenesis and assembly**
 - Regulates the **localization of S protein** at cis-Golgi, the place of virus budding.
- **ORF6 protein (ORF6)**
 - Disrupts cell nuclear import complex formation by tethering karyopherin alpha 2 and karyopherin beta 1 to the membrane. **blocking the expression of interferon stimulated genes (ISGs)** that display multiple antiviral activities



- ORF7a protein (ORF7a)

- **antagonist of host tetherin (BST2)**, disrupting its antiviral effect. May suppress small interfering RNA (siRNA)




- ORF7b protein (ORF7b)

- No known function – **locates to host Golgi and host endosome**


- ORF8 protein (ORF8)

- Binds to IL17RA receptor, leading to IL17 pathway activation and an increased secretion of pro-inflammatory factors. **Contributes to cytokine storm during COVID-19 infection..**




- Nucleoprotein (N)

- **Packages the positive strand viral genome RNA** into a helical ribonucleocapsid (RNP) and plays a fundamental role during viric assembly through its interactions with the viral genome and membrane protein M



- ORF9b protein (ORF9b)

- **inhibition of host innate immune** response by targeting the mitochondrial-associated adapter MAVS



- ORF9c protein (ORF9c)

- May play a role in **host-virus interaction.**

- ORF10 protein


- No known function

Interactions
with Human cells

Reakce organismu na SARS-CoV-2

- **Replikace viru** - [WP4846](#)
- **Viral subversion of host defence:**
 - ER stress and unfolded protein response - [WP4861](#)
 - Autophagy and protein degradation - [WP4860](#), [WP4936](#), [WP4863](#)
 - Apoptosis - [WP4864](#)
- **Integrative stress response:**
 - Renin-angiotensin - [WP4883](#), [WP4965](#)
 - Coagulopathy - [WP4927](#)
- **Innate Immune Response:**
 - PAMP signalling - [WP4912](#)
 - Induction of interferons and the cytokine storm - [WP4868](#), [WP4880](#), [WP4876](#)
 - Altered host metabolism - [WP4853](#)


Wikipathways





<https://www.wikipathways.org/index.php/Pathway:WP4846#nogo2>

<https://www.embopress.org/doi/full/10.15252/msb.202110387>

Interacting proteins



SARS-CoV-2 S protein + ACE2






- Hlavní kontakt s buňkami

Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, et al. (2020) COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLOS Pathogens 16(8): e1008762. <https://doi.org/10.1371/journal.ppat.1008762>

<https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008762>

ACE2 – what is it? Why do we care?

Renin-angiotensin system



Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2








Fig. 1. 293T cell clones expressing ACE2 at different levels. (A) ACE2 expression in 293T cells engineered to express different levels of ACE2. ACE2 surface expression was measured by flow cytometry, and the histograms show the distribution of expression levels over a population of cells. Vero E6 cells are included for comparison. **(B)** Relationship between ACE2 expression in the four 293T target cell clones and infection by lentiviral particles pseudotyped with the SARS-CoV-2 D614G spike.

Expression of ACE2




Weird, right?





a**b**



List of epithelial cells



Viera Braga et al.²⁶ dataset





Deprez et al.²⁷ dataset




Co.

Intermediates in SARS-CoV-2 spike-mediated cell entry



Spike protein in detail

Conformers S proteins




Ke, Z., Oton, J., Qu, K. *et al.*
Structures and distributions of SARS-CoV-2 spike proteins on intact virions.



Nature **588**, 498–502 (2020).

<https://www.nature.com/articles/s41586-020-2665-2/figures/2>

Glycosylation




Mutace S proteinu



Antibodies

Interaction with antibodies

- **Neutralizing** antibodies binds with RBD domain – blocking ACE2 interaction



pdbid:8dzi

Protilátky



CoV-AbDab

The Coronavirus Antibody Database

B Downloads

- [Database \(CSV\)](#)
- [ANARCI Numberings \(.json\)](#)
- [PDB Structures \(.tar.gz\)](#)
- [Homology Models \(.tar.gz\)](#)
- [Tracked Datasets \(.xlsx\)](#)

D Search Database by Attribute

To view all entries, leave all search fields as 'All' and click 'Search'.

Type	All
Binds to	All
Doesn't bind to	All
Neutralising against	All
Not neutralising against	All
Protein/Epitope	All
Origin	All
Heavy V Gene	All
Heavy J Gene	All
Light V Gene	All
Light J Gene	All

[Search](#)

C Search Database by Sequence

Enter a sequence (either a full-length variable your query.
Only database entries that use the same len

Query sequence:
`DVGLVSGAEVQQRGASVYVCKRASCYTFE`


E

Show 10 entries Search: Yan Wu et al, 2020


Heavy V Gene	Heavy J Gene	Light V Gene	Light J Gene	CDRL1	CDRL2	Structures	AbB Homology Model
IGHV3-53 (Human)	IGHJ6 (Human)	IGKV1-9 (Human)	IGKJ2 (Human)	AREKAFQNDV	QQLNSYPPVT	PDB entry 7B25 [7B25] [SAbDab]	
IGHV1-2 (Human)	IGHJ2 (Human)	IGKV2-40 (Human)	IGKJ4 (Human)	ARIYFCSSTSCHEKDFFL	HQRTEFFLT	NO	download or view

F

Database Entry	CDR	Sequence Identity	Ab or Mb	Binds to																											
B38	H3	100,00%	Ab	SARS-CoV2																											
<table border="1"> <tr><td>185</td><td>186</td><td>187</td><td>188</td><td>189</td><td>114</td><td>115</td><td>116</td><td>117</td></tr> <tr><td>A</td><td>R</td><td>E</td><td>A</td><td>Y</td><td>G</td><td>R</td><td>D</td><td>Y</td></tr> <tr><td>A</td><td>R</td><td>E</td><td>A</td><td>Y</td><td>G</td><td>R</td><td>D</td><td>Y</td></tr> </table>					185	186	187	188	189	114	115	116	117	A	R	E	A	Y	G	R	D	Y	A	R	E	A	Y	G	R	D	Y
185	186	187	188	189	114	115	116	117																							
A	R	E	A	Y	G	R	D	Y																							
A	R	E	A	Y	G	R	D	Y																							
C148	H3	66,67%	Ab	SARS-CoV2																											
<table border="1"> <tr><td>185</td><td>186</td><td>187</td><td>188</td><td>189</td><td>114</td><td>115</td><td>116</td><td>117</td></tr> <tr><td>A</td><td>R</td><td>E</td><td>A</td><td>Y</td><td>G</td><td>R</td><td>D</td><td>Y</td></tr> <tr><td>A</td><td>R</td><td>I</td><td>A</td><td>N</td><td>Y</td><td>R</td><td>D</td><td>Y</td></tr> </table>					185	186	187	188	189	114	115	116	117	A	R	E	A	Y	G	R	D	Y	A	R	I	A	N	Y	R	D	Y
185	186	187	188	189	114	115	116	117																							
A	R	E	A	Y	G	R	D	Y																							
A	R	I	A	N	Y	R	D	Y																							




Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses




Spike protein interactions with

● glycosylation ● ACE2 ● antibodies ● antigens ● mutation counts



Escape calculator for SARS-CoV-2 RBD



eliciting virus

known to neutralize

weight by log IC50 yes no

mutation_escape_strength

https://jbloomlab.github.io/SARS2_RBD_Ab_escape_maps/escape-calc/

<https://academic.oup.com/ve/article/8/1/veac021/6549895>

Genomic surveillance


Variants - Genomes SARS-Cov-2

Genomic epidemiology of SARS-CoV-2 with subsampling focused globally over the past 6 months


Built with nextstrain/ncov. Maintained by the Nextstrain team. Enabled by data from  GISAID.

Showing 2912 of 2912 genomes sampled between Dec 2019 and Aug 2022.


Phylogeny



Geography



Diversity



<https://nextstrain.org/ncov/global?m=div>

Varianty v ČR

Datum odběru (prosím vložte obě hodnoty)

1. 5. 2022

21. 11. 2022

Linie (vyberte jednu nebo více)

Klikni sem

Typ grafu

Absolutní Relativní

Kumulativní

Zastoupení linií


Vše Minimálně 1% Minimálně 5%

Minimálně 10%

Seskupení v čase


Týdně

Měsíčně



Therapeutics


Clinical trials





Drugs	No. of clinical trials registered ^a	Phase	Molecular target	Development strategy	Approval status (for COVID-19)
Remdesivir	77	4	RdRp	Repurposing	Approval by FDA
Favipiravir	46	4	RdRp	Repurposing	EUA in several countries
Molnupiravir	5	3	RdRp	Novel	Approval by MHRA; EUA by FDA
AT-527	3	3	RdRp	Novel	Non-approved
Galidesivir	1	1	RdRp	Repurposing	Non-approved
Sofosbuvir	8	4	RdRp	Repurposing	Non-approved
Azvudine	3	3	RdRp	Repurposing	Non-approved
Tenofovir/emtricitabine	5	3	RdRp	Repurposing	Non-approved
PF-07321332	8	3	3CLpro	Novel	EUA by FDA
PF-07304814	3	1	3CLpro	Novel	Non-approved
s-217622	—	2/3	3CLpro	Novel	Non-approved
FB2001	1	2/3	3CLpro	Novel	Non-approved
Ebselen	2	2	3CLpro	Repurposing	Non-approved
Lopinavir/ritonavir	24	4	3CLpro	Repurposing	Non-approved
Triazavirin	2	4	RNA synthesis/3CLpro	Repurposing	Non-approved
Chloroquine/hydroxychloroquine	46/276	4	Endosomal entry	Repurposing	EUA by FDA at earlier outbreak (chloroquine)
Umifenovir/arbidol	3	4	Endosomal entry	Repurposing	Non-approved
Niclosamide	11	3	Endosomal entry	Repurposing	Non-approved
Chlorpromazine	2	3	Endosomal entry	Repurposing	Non-approved
Baricitinib	20	4	Endosomal entry	Repurposing	EUA by FDA
Proxalutamide	5	3	Androgen receptor antagonist	Repurposing	Non-approved
Dutasteride	1	2	5-alpha-reductase inhibitor	Repurposing	Non-approved
Camostat mesylate	5	3	TMPRSS2 inhibitor	Repurposing	Non-approved
Nafamostat mesylate	2	2	TMPRSS2 inhibitor	Repurposing	Non-approved
PTC299	1	2	DHODH inhibitor	Repurposing	Non-approved
Teriflunomide	3	3	DHODH inhibitor	Repurposing	Non-approved
Nitazoxanide	23	4	Endosomal entry/Inflammatory response regulation	Repurposing	Non-approved
Fluvoxamine	1	3	Sigma-1 receptors agonist	Repurposing	Non-approved
Plitidepsin	3	3	eEF1A inhibitor	Repurposing	Non-approved
Ivermectin	69	4	IMPA/β1 inhibitor	Repurposing	Non-approved
Apilimod	1	2	PIKFYVE inhibitor	Repurposing	Non-approved

^aRegistered on *ClinicalTrials.gov*.

Cryo-EM RdRp of SARS-CoV-2.





Remdesivir




Molnupiravir

- Pilulka
- Blokuje replikaci SARS-CoV-2
- Žádné závažné vedlejší efekty na dobrovolnících
- prevence hospitalizace se závažnými formami a smrtí




Molnupiravir MoA




Kabinger, F., Stiller, C., Schmitzová, J. *et al.* Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. *Nat Struct Mol Biol* **28**, 740–746 (2021). <https://doi.org/10.1038/s41594-021-00651-0>

Paxlovid vs Molnupiravir



1 Attachment and entry



2 Translation of viral proteins





3 Proteolysis



Chemical structure


4 RNA replication

Replication transcription complex




molnupiravir (Merck)


5 Transcription and translation of structural and accessory proteins



6 Assembly, packaging, and release




Protease Inhibitors – Spike and Maturation



Vakcíny

AN ARRAY OF VACCINES




* Other efforts include testing whether existing vaccines against poliovirus or tuberculosis could help to fight SARS-CoV-2 by eliciting a general immune response (rather than specific adaptive immunity), or whether certain immune cells could be genetically modified to target the virus.

©nature

Vakcíny ve vývoji

Coronavirus Vaccine Tracker

By [Carl Zimmer](#), [Jonathan Corum](#), [Sui-Lee Wee](#) and Matthew Kristoffersen Updated Aug. 31, 2022



<https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

Vakcíny I


VIRUS VACCINES

Weakened virus

A virus is conventionally weakened for a vaccine by being passed through animal or human cells until it picks up mutations that make it less able to cause disease. Codagenix in Farmingdale, New York, is working with the Serum Institute of India, a vaccine manufacturer in Pune, to weaken SARS-CoV-2 by altering its genetic code so that viral proteins are produced less efficiently.

Inactivated virus

In these vaccines, the virus is rendered uninfected using chemicals, such as formaldehyde, or heat. Making them, however, requires starting with large quantities of infectious virus.




VIRAL-VECTOR VACCINES

Replicating viral vector (such as weakened measles)

The newly approved Ebola vaccine is an example of a viral-vector vaccine that replicates within cells. Such vaccines tend to be safe and provoke a strong immune response. Existing immunity to the vector could blunt the vaccine's effectiveness, however.

Non-replicating viral vector (such as adenovirus)


No licensed vaccines use this method, but they have a long history in gene therapy. Booster shots can be needed to induce long-lasting immunity. US-based drug giant Johnson & Johnson is working on this approach.



Sputnik V - two adenovirus vectors with Spike protein- rAd26-S + rAd5-S

Vakcíny II

NUCLEIC-ACID VACCINES




Pfizer-BioNtech – mRNA for Spike protein
 Moderna - mRNA-1273 for Spike protein

PROTEIN-BASED VACCINES


Protein subunits

Twenty-eight teams are working on vaccines with viral protein subunits – most are focusing on the virus's spike protein or a key part of it called the receptor binding domain. Similar vaccines against the SARS virus protected monkeys against infection but haven't been tested in people. To work, these vaccines might require adjuvants – immune-stimulating molecules delivered alongside the vaccine – as well as multiple doses.



Virus-like particles

Empty virus shells mimic the coronavirus structure, but aren't infectious because they lack genetic material. Five teams are working on 'virus-like particle' (VLP) vaccines, which can trigger a strong immune response, but can be difficult to manufacture.



Leading vaccines

Developer	How It Works	Phase	Status
 Pfizer-BioNTech	mRNA	3	Approved in U.S., other countries. Emergency use in many countries.
 Sinopharm	Inactivated	3	Approved in China, Bahrain. Emergency use in many countries.
 Oxford-AstraZeneca	ChAdOx1	2 3	Approved in Brazil, India. Emergency use in many countries.
 Sinovac	Inactivated	3	Approved in China. Emergency use in many countries.
 Moderna	mRNA	3	Approved in U.S., Canada, Switzerland. Emergency use in many countries.
 Novavax	Protein	3	Approved in Canada, South Korea. Emergency use in several countries.
 Bharat Biotech	Inactivated	3	Approved in India. Emergency use in other countries.
 Johnson & Johnson	Ad26	3	Approved in Canada. Limited in U.S. Emergency use in many countries.
 Baylor-Biological E	Protein	3	Emergency use in India, Botswana.
 Gamaleya	Ad26, Ad5	3	Approved in Russia. Emergency use in many countries.


Zamítnuté vakcíny – zvláštní zmínka

ABANDONED



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

CSL



- Opuštěna 10.12.2020
- Na křečcích fungovala skvěle
- Fáze I – červenec 2020 – skvělé, hodně protilátek, žádné závažné vedlejší účinky
- Ale pak – dobrovolníci začali mít pozitivní testy na HIV, aniž by HIV virus měli
- Důvod: Aby udrželi S protein ve správném tvaru – drželi ho na místě pomocí „molecular clamp“ – ke kterému použili segment HIV proteinu – a ten chytaly protilátkové testy na HIV

Summary

Závěry

- Máme už docela dobrou představu ohledně struktury a funkce drtivé většiny proteinů SARS-CoV-2
- Vede to k návrhu léčiv a vakcín
- Sledováním mutací můžeme odhalit, které protilátky už na nové varianty nebudou plně fungovat
- Bohužel ani po nákaze tolika lidí stále má virus i v rámci RBD domény kde mutovat...



Zdroje

- virus.img.cas.cz
- covid19dataportal.org
- pdb101.rcsb.org/teach/covid-19
- pdb101.rcsb.org/sci-art/goodsell-gallery
- swissmodel.expasy.org/repository/species/2697049
- ebi.ac.uk/pdbe/covid-19
- [http://home.sandiego.edu/~josephprovost/BiochemCovid Teaching.html](http://home.sandiego.edu/~josephprovost/BiochemCovidTeaching.html)

Imunita

VACCINE BASICS: HOW WE DEVELOP IMMUNITY

The body's adaptive immune system can learn to recognize new, invading pathogens, such as the coronavirus SARS-CoV-2.






Genome SARS-Cov-2

Genomic epidemiology of novel coronavirus - Global subsampling


Built with [nextstrain/ncov](#). Maintained by the [Nextstrain team](#). Enabled by data from [GISAID](#).

Showing 3572 of 3572 genomes sampled between Dec 2019 and Oct 2021.





<https://nextstrain.org/ncov/global?m=div>




Varianty v ČR



SARS, MERS, COVID-19 “parts list”





Klasifikace a struktury koronaviřů



Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, et al. (2020) COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. *PLOS Pathogens* 16(8): e1008762. <https://doi.org/10.1371/journal.ppat.1008762>

<https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008762>

Spike Protein




Receptor-binding domain

S1 subunit

S2 subunit


Polybasic cleavage site

b



O-linked glycan residues

a




Detail komplexu proteinů viru

- Nsp3 -- a multidomain protein that includes RNA-binding domains, a membrane-anchoring domain, and the papain-like protease
- Nsp4 and 6 -- membrane-spanning proteins that remodel the ER membrane
- Nsp5 -- main protease that cuts the viral polyproteins into functional pieces
- Nsp7, 8 and 10 -- proteins involved in organizing the replicase complex
- Nsp12 -- RNA-directed RNA polymerase creates new viral RNA strands
- Nsp13 -- helicase separates strands in an RNA double helix
- Nsp14 -- guanine N7-methyltransferase includes an exoribonuclease involved in proofreading
- Nsp15 -- uridylate-specific endoribonuclease breaks RNA, the function of which is still under study
- Nsp16 -- 2'-O-methyltransferase is involved in formation of the RNA cap

Three structural proteins are also shown:

- Nucleocapsid (N) condenses the viral genomic RNA
- Membrane (M) protein works with N to package the RNA into the virion
- Envelope (E) is involved in the process of budding

sizes and shapes of each protein are based on current structural information, but the arrangement within the complex is largely speculative:



Several accessory proteins (p6, p7a, and p8a) are also shown. These are dispensable for replication of the virus, but are involved in the virulence of infection.